Health Headlines Roundup: Legal Wins, Market Moves, and Urgent Warnings

A summary of current health news, including an Australian judge dismissing a Roundup lawsuit, the impact of extreme heat on medications, Mankind Pharma's acquisition, and Roche boosting profit guidance. Additional topics cover EU state aid for a new Dutch nuclear reactor, bird flu infections, a UN agency's bird flu warning, Novo's heart-risk drug approval, Brazil's end to a disease outbreak, and Indivior's profit surge.

An Australian judge on Thursday dismissed a class action lawsuit claiming Bayer's Roundup weedkiller can cause a type of blood cancer, a ruling the company aims to leverage in U.S. cases.

Prolonged climate change-induced heat waves can alter medications and their effects on patients. The world just experienced its hottest day on record, highlighting the issue.

Indian drugmaker Mankind Pharma has announced a $1.6 billion acquisition of Bharat Serums and Vaccines Ltd, expanding its healthcare product range.

Roche has raised its 2024 profit forecast due to strong sales of new drugs like the eye medicine Vabysmo, expecting high single-digit earnings growth.

The Dutch government is set to receive EU approval for a $2.2 billion state aid package to build a nuclear reactor for medical isotope production, conditional on cost-selling pledges.

Three new bird flu cases have been confirmed among Colorado poultry farm workers, bringing this year's U.S. total to 13, with mild symptoms reported and antiviral drugs offered.

The UN's Food and Agriculture Organization has called for an urgent response to the widespread H5N1 avian flu, affecting both humans and animals globally.

The EU regulator has approved Novo Nordisk's Wegovy for reducing cardiovascular risks in overweight or obese adults, following similar approvals in the UK and U.S.

Brazil is set to declare the end of a Newcastle disease outbreak in the southern state of Rio Grande do Sul, according to an agriculture ministry official.

Indivior's share prices soared as it announced a $100 million buyback amidst rising profits from its opioid addiction treatment Sublocade, which saw a 24% revenue increase in Q2.

(With inputs from agencies.)